SOPHiA DDM™ Community CLL Clonality Solution: The importance of biomarker analysis in Chronic Lymphoblastic Leukemia
Lymphoid neoplasms encompassing lymphomas and some leukemia like Chronic Lymphocytic Leukaemia (CLL) are the most common type of blood cancer .
With increasing evidence for the stratification of tumor types with distinct clinical and biological features according to biomarkers, and the progress in targeted therapy, tailored NGS-based workflows empower experts to get high-quality and reproducible data to accelerate their studies. Watch our “SOPHiA DDM™ Community CLL Clonality Solution: The importance of biomarker analysis in CLL” webinar by Dr. Ferran Nadeu, Fundació de Recerca Clínic Barcelona-IDIBAPS, Molecular Pathology of Lymphoid Neoplasms Research Group.
Ferran Nadeu received his PhD from the University of Barcelona. He is a post-doctoral researcher at the Fundació de Recerca Clínic Barcelona - IDIBAPS. Dr. Nadeu has published 66 articles in top journals in the field of cancer genomics and...
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare diseases management, the universal SOPHiA DDM Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1,000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA GENETICS’s achievement is recognized by the MIT Technology Review’s "50 Smartest Companies".